Skip to content
Peptigraph home

Cagrilintide Phase 1 trial (NCT04209049)

An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal Function

Registry record checked

At a glance

Phase
Phase 1
Status
Completed
Enrolment
33
actual
Start
15 Jan 2020 (actual)
Primary completion
5 Jan 2021 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT04209049 study arms
ArmTypeInterventionsDescription
Normal renal functionExperimentalDrug: NNC0174-0833All subjects will receive one dose of NNC0174-0833.
Mild renal impairmentExperimentalDrug: NNC0174-0833All subjects will receive one dose of NNC0174-0833.
Moderate renal impairmentExperimentalDrug: NNC0174-0833All subjects will receive one dose of NNC0174-0833.
Severe renal impairmentExperimentalDrug: NNC0174-0833All subjects will receive one dose of NNC0174-0833.
Endpoints

Primary endpoint

NCT04209049 primary outcomes
MeasureTime frame
Area under the plasma NNC0174-0833 concentration-time curve after a single doseFrom baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36)
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04209049 secondary outcomes
MeasureTime frame
Maximum observed plasma NNC0174-0833 concentration after a single doseFrom baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (visit 7, Day 36)
Time to maximum observed plasma NNC0174-0833 concentration after a single doseFrom baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36)
Number of treatment emergent adverse events (TEAEs)From time of trial product administration (Visit 2, Day 1) until completion of the end of trial visit (Visit 7, Day 36)
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Results

Results

No results posted on ClinicalTrials.gov as of 11 Oct 2026.

Renal impairment and a single cagrilintide dose

Both impairment studies sorted adults into four function groups and gave a single cagrilintide injection of 0.6 mg or 0.9 mg.[2]

The kidney arm enrolled 33 people: 14 with normal function, 7 mild, 7 moderate and 5 severe impairment.[2]

Compared with normal kidney function, mean AUC ratios were 1.23, 1.18 and 1.21 for mild, moderate and severe impairment.[2]

Sources

  1. 1An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal FunctionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
  2. 2Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026

Found an error? Report a correction.